CLOBETASOL PROPIONATE lotion

Ország: Egyesült Államok

Nyelv: angol

Forrás: NLM (National Library of Medicine)

Vedd Meg Most

Termékjellemzők Termékjellemzők (SPC)
31-10-2019

Aktív összetevők:

clobetasol propionate (UNII: 779619577M) (Clobetasol - UNII:ADN79D536H)

Beszerezhető a:

Taro Pharmaceuticals U.S.A., Inc.

INN (nemzetközi neve):

clobetasol propionate

Összetétel:

clobetasol propionate 0.5 mg in 1 mL

Az alkalmazás módja:

TOPICAL

Recept típusa:

PRESCRIPTION DRUG

Terápiás javallatok:

Clobetasol propionate lotion, 0.05% is a super-high potent topical corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses only in patients 18 years of age or older. Treatment should be limited to 2 consecutive weeks. For moderate to severe plaque psoriasis, treatment may be extended for an additional 2 weeks for localized lesions (less than 10% body surface area) that have not sufficiently improved after the initial 2-week treatment. Any additional benefits of extending treatment should be weighed against the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression before prescribing for more than 2 weeks. The total dosage should not exceed 50 g (50 mL or 1.75 fl. oz) per week. Patients should be instructed to use clobetasol propionate lotion, 0.05% for the minimum amount of time necessary to achieve the desired results [see Dosage and Administration (2) ]. Use in patients under 18 years of age is not recommended due to

Termék összefoglaló:

Clobetasol Propionate Lotion, 0.05% is a white lotion supplied in the following sizes: 2 fl oz (59 mL) NDC 51672-1350-4 high density polyethylene bottles 4 fl oz (118 mL) NDC 51672-1350-8 high density polyethylene bottles Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from freezing.

Engedélyezési státusz:

Abbreviated New Drug Application

Termékjellemzők

                                CLOBETASOL PROPIONATE- CLOBETASOL PROPIONATE LOTION
TARO PHARMACEUTICALS U.S.A., INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
CLOBETASOL PROPIONATE LOTION,
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
CLOBETASOL PROPIONATE LOTION.
CLOBETASOL PROPIONATE LOTION, FOR TOPICAL USE
INITIAL U.S. APPROVAL: 1985
INDICATIONS AND USAGE
Clobetasol propionate lotion, 0.05% is a corticosteroid indicated for
the relief of the inflammatory and pruritic
manifestations of corticosteroid-responsive dermatoses, in patients 18
years of age or older (1.1).
Limitations of Use:
Do not use on the face, axillae or groin. (1.2)
Do not use if atrophy is present at the treatment site. (1.2)
Do not use for rosacea or perioral dermatitis. (1.2)
DOSAGE AND ADMINISTRATION
Not for oral, ophthalmic, or intravaginal use. (2)
Clobetasol propionate lotion, 0.05% should be applied directly onto
the affected skin areas twice daily and rubbed in
gently. (2)
Clobetasol propionate lotion, 0.05% contains a super-high potent
topical corticosteroid; therefore treatment should be
limited to 2 weeks.
For moderate to severe plaque psoriasis, treatment may be extended for
additional 2 weeks for localized lesions (<10%
body surface area) that have not sufficiently improved. (2)
Total dosage should not exceed 50 g (50 mL or 1.75 fl. oz.) per week.
(2)
DOSAGE FORMS AND STRENGTHS
Lotion, 0.05% w/w (3)
CONTRAINDICATIONS
None (4)
WARNINGS AND PRECAUTIONS
Clobetasol propionate is a highly potent topical corticosteroid that
has been shown to suppress the hypothalamic-pituitary-
adrenal (HPA) axis at the lowest doses tested. (5.1)
Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes
mellitus can also result from systemic absorption of
topical corticosteroids. (5.1)
Systemic absorption may require periodic evaluation for HPA axis
suppression. Modify use if HPA axis suppression
develops. (5.1)
Children may be more susceptible to systemic toxicity from use of
topical co
                                
                                Olvassa el a teljes dokumentumot
                                
                            

A termékkel kapcsolatos riasztások keresése

Dokumentumelőzmények megtekintése